Devices address both tissue shortage and transplant demand
Novaliq and Laboratoires Théa announce European Commission approval of ciclosporin 0.1% eye drops solution
Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease
Novel therapies emerge for a progressive corneal disease
Current and future options for Fuchs endothelial corneal dystrophy
Aurion Biotech announces commercial launch of neltependocel (Vyznova) in Japan
Neltependocel has received both regulatory and reimbursement approval in Japan
ESCRS 2024: Approaching a paradigm shift in cell therapy for corneal oedema and endothelial dysfunction
Michael Goldstein, MD, discusses 12-month safety and efficacy trial data of human corneal endothelial cell therapy, presented at the 2024 ESCRS Congress
Magnetic cell therapy for corneal endothelial dysfunction
Phase 1 multicentre study data demonstrate early signs of efficacy
European Commission grants marketing authorization for treatment of acanthamoeba keratitis
Akantior, an anti-amoebic polymer eye drop, is the first and only authorised medical product for the treatment of AK in the world, according to a news release.
